RATIONALE: Childhood wheezing disease is a bothering airway problem and may prelude by bronchiolitis and progress to childhood asthma. Macrolides have both antimicrobial and anti-inflammatory functions and have been used as adjunctive therapy in childhood wheezing disease. METHODS: We conducted a meta-analysis to evaluate the long-term effect of macrolide in children with wheezing disease. Literatures research were systemically conducted using electronic database from inception to August 2018. Cochrane Review risk of bias assessment tool was used to assess RCTs quality. RESULTS: Sixteen RCTs comprising 1415 participants were investigated in a meta-analysis. Macrolides therapy significantly preserved more pulmonary functions in both FEV1% (difference in means (MD) 5 -9.77, 95% CI 5 -14.18 to -5.35, p< 0.001; I 2 5 0%) and FEF25-75% (MD 5 -14.14, 95% CI 5 -26.11 to -2.18, p5 0.02; I 2 5 29.56%). RATIONALE: Omalizumab reduces exacerbations in patients with moderate-to-severe allergic asthma, with a more pronounced response observed with higher baseline eosinophils and asthma severity. We examined omalizumab-associated changes in eosinophil levels by baseline blood eosinophil levels and asthma severity. METHODS: Post-hoc analysis assessed the longitudinal effects of omalizumab on eosinophils by baseline eosinophil levels (<150, 150-299, 300-399, and > _400 cells/mL) and asthma severity (history of emergency asthma treatment or hospitalization, and LABA use [yes/no], and above/below median % predicted FEV1) in three Phase III placebocontrolled omalizumab trials. Data from IA05 (steroid stable phase, ages 6-11; n5562) were available for baseline, Week 5 and 13 and pooled data from INNOVATE and EXTRA (ages 12-75; n51094) for baseline, Week 12/16 and 28/32. RESULTS: Median baseline eosinophil levels were similar for omalizumab and placebo-treated groups in all subgroups examined. Omalizumab reduced eosinophils more than placebo in patients with baseline eosinophils >150 cells/mL. The largest median [IQR] reductions were observed in patients with > _400 cells/ml by Week 5 for IA05 (-200 METHODS: Healthy men and women (18-55 years old; N5180) were randomized to 1 of 6 combinations of device (APFS or AI) and injection site (upper arm, abdomen, or thigh). Randomization was stratified by weight: <70 kg, 70-84.9 kg, and > _85 kg. Serum benralizumab concentrations were determined on Days 1 (pre-dose), 2, 4, 5, 6, 8, 15, 29, 43, and 57. RESULTS: Benralizumab pharmacokinetic exposure was similar between devices, with geometric mean ratios (AI/APFS) (90% CIs) of 92.8% (87.4-98.6), 94.5% (88.2-101.2), and 92.3% (86.3-98.8) for two area under the concentration-time curve measurements (AUC last and AUC inf ) and maximum observed concentration (C max ), respectively. All 90% CIs were within the 80-125% reference range. Exposure was approximately 15-30% greater for thigh administration than abdomen/upper arm and slightly greater for APFS than AI. These differences were observed only for the low-and medium-weight groups. These differences are unlikely to be clinically relevant as eosinophil depletion was achieved consistently with both devices at all injection sites. No device malfunctions were reported. No new or unexpected safety findings were observed. CONCLUSIONS: Benralizumab pharmacokinetic exposure was similar whether APFS or AI were used to administer a single SC dose to healthy volunteers.
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